KOSPIFood & Beverage097950

CJ Cheiljedang

₩184,000▲ 0.93%2026-11-18 close
Market Cap
₩2.8T
Turnover
₩7.2B
Volume
40K
Shares out.
15.1M
PER
—
PBR
0.4×
EPS
-₩45,759
Dividend Yield
3.43%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩6,000 per share · Prices as of the 2026-11-18 close

01

Report overview

Operating Profit Up Three Straight Quarters; Net Profit Recovery Still Pending

CJ Cheiljedang's operating profit has risen for three consecutive quarters since the fourth quarter of 2025, but quarterly net profit attributable to owners is still mixed, and bio pricing and food profitability remain the key variables to watch.

  1. 1

    Operating profit rose from KRW 204.8 billion in the fourth quarter of 2025 to KRW 309 billion in the third quarter of 2026, marking three consecutive quarterly increases.

  2. 2

    Net profit attributable to owners returned to a KRW 19.2 billion profit in Q3 2026 after a KRW 13.5 billion loss in Q2, but the four most recent quarters total a KRW 733.2 billion attributable net loss.

  3. 3

    The company swung to an attributable net loss of KRW 571.5 billion in 2025, and the debt-to-equity ratio stood at 157.5% at year-end 2025.

  4. 4

    Overseas food sales reached KRW 5.92 trillion in 2025, or 51.4% of food sales, which press reports described as the first time the overseas share passed half.

  5. 5

    Bio segment operating profit fell to KRW 5.5 billion in Q1 2026, down 92.4% year on year, while the core materials unit recovered to KRW 108.5 billion in Q3 2026.

02

Business structure

CJ Cheiljedang is a food company built on two pillars, food and bio-based materials. The business is reported in three segments: Lifestyle Foods, Technical Solution and Performance Ingredients.

In Q3 2026 Lifestyle Foods booked sales of KRW 2.57 trillion and operating profit of KRW 118.7 billion, excluding the logistics subsidiary. Overseas food sales reached KRW 5.92 trillion in 2025, or 51.4% of food sales, which press reports described as the first time the overseas share passed half.

Global strategic products such as dumplings, packaged rice, kimchi, seaweed and noodles drove that growth. The food segment recorded sales of KRW 11.52 trillion and operating profit of KRW 525.5 billion in 2025.

Performance Ingredients posted sales of KRW 1.423 trillion and operating profit of KRW 108.5 billion in Q3 2026, with lysine and tryptophan as core amino acids and specialty amino acids such as arginine, histidine and valine added on top.

Specialty product sales grew at an average annual rate of 28% from the first quarter of 2020, lifting their share of total sales from 11% to 18%.

Technical Solution covers nucleotide seasonings, TNR, health and wellness products and the biodegradable PHA material, and it posted sales of KRW 232.6 billion and an operating loss of KRW 24.2 billion in Q3 2026.

Feed-grade amino acids face price pressure from low-cost bulk supply out of China, which the company said made 2025 the low point. In October 2025 the company disclosed a sale agreement for 100% of its feed subsidiary CJ Feed&Care to a Dutch feed company.

Competitiveness in food depends on how fast the company reaches new retail channels overseas, while in bio it depends on cost competitiveness.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩7.4T₩346.5B4.7%
2025Q4₩5.5T₩204.8B3.8%
2026Q1₩7.1T₩238.1B3.3%
2026Q2₩7.4T₩257.6B3.5%
2026Q3₩7.4T₩309B4.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩30.1T₩1.7T₩802.7B5.5%11.9%160.3%
2023₩29T₩1.3T₩385.9B4.5%5.4%151.3%
2024₩29.4T₩1.6T₩148.2B5.3%1.9%146.3%
2025₩27.3T₩1.2T-₩571.5B4.5%−8.1%157.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a DART-disclosed basis, annual sales went from KRW 30.1 trillion in 2022 to KRW 29 trillion in 2023 (down 3.5% year on year), KRW 29.4 trillion in 2024 (up 1.2%) and KRW 27.3 trillion in 2025 (down 6.9%). Among 2022 to 2025, 2022 was the largest year and 2025 the smallest.

Operating profit went from KRW 1.66 trillion in 2022 to KRW 1.29 trillion in 2023 (down 22.4%), recovered to KRW 1.55 trillion in 2024 (up 20.2%) and fell to KRW 1.23 trillion in 2025 (down 20.6%).

The operating margin was 5.5% in 2022, 4.5% in 2023, 5.3% in 2024 and 4.5% in 2025, so margin movements rather than sales drove profit.

Net profit attributable to owners fell from KRW 802.7 billion in 2022 to KRW 385.9 billion in 2023 (down 51.9%) and KRW 148.2 billion in 2024 (down 61.6%), then swung to a net loss of KRW 571.5 billion in 2025. Net profit including non-controlling interests was a net loss of KRW 417 billion in 2025.

Operating cash flow stayed in the KRW 2 trillion range from 2023 to 2025, at KRW 2.44 trillion, KRW 2.26 trillion and KRW 2.48 trillion.

On a quarterly basis, operating profit bottomed at KRW 204.8 billion in Q4 2025, down 40.9% from the prior quarter, and then rose to KRW 238.1 billion in Q1 2026, KRW 257.6 billion in Q2 and KRW 309 billion in Q3, three consecutive increases.

Q3 operating profit was still down 10.8% from the same quarter of the prior year. Net profit attributable to owners swung between quarters: a KRW 820.6 billion loss in Q4 2025, a KRW 81.8 billion profit in Q1 2026, a KRW 13.5 billion loss in Q2 and a KRW 19.2 billion profit in Q3, which was down 73.7% year on year.

The four most recent quarters total a KRW 733.2 billion attributable net loss. The company attributed the Q3 bottom-line drag to foreign exchange valuation losses, while freight and raw material costs were cited as additional pressure.

Bio profit fell 92.4% to KRW 5.5 billion in Q1 2026 and then recovered to KRW 108.5 billion in Q3 for the core materials unit, showing how sharply pricing moves affect quarterly results. The drivers behind the size of the Q4 2025 loss are items to confirm in the notes to the annual report.

05

Industry analysis

The bio segment is strongly exposed to the amino acid price cycle. The company said 2025 was the low point for feed-grade amino acid prices. Press reports said the prices of major products such as methionine and lysine turned upward in 2026, though those gains reach reported profit with a lag.

Low-cost bulk production in China still caps how far prices can recover. Specialty amino acids have grown structurally, at an average annual rate of 28% from the first quarter of 2020. The food segment relies on overseas K-food demand while domestic consumption remains weak for an extended period.

Overseas food sales set a record in 2025 according to press reports. In Q1 2026 sales in Europe and Asia-Pacific each grew 17%, which supports the overseas expansion case. Freight and packaging costs have risen with war-related disruption and higher oil prices.

Brokerage analysts described food as the stable earnings base and bio as a business whose profit swings sharply with prices. Because overseas sales are already large, analysts see gradual expansion rather than rapid growth.

06

Outlook

The company expects Q4 2026 sales, excluding the logistics subsidiary, to rise in the low single digits year on year, with an operating margin in the 5% range. By segment, the technical solutions unit is expected to post its strongest quarter of the year during the nucleotide peak season.

Lifestyle Foods plans to keep expanding global sales led by dumplings and packaged rice. Performance Ingredients aims to lift profitability by growing specialty product sales and securing competitive advantage and new demand.

A press report from April 2026 said the industry expected results to stay weak through the first half and recover gradually from the second half. Restructuring is also under way.

A sale agreement for the feed subsidiary was disclosed in October 2025, and a report from early 2026 said the F&C division would be classified as discontinued operations from the fourth quarter if its sale closes. A new Hungary plant is reported to start operating in 2027.

Based on last year's timing, when full-year results were released in early February 2026, the 2026 fourth-quarter and full-year results are likely in early February 2027. The 2026 annual report must be filed by the end of March 2027 under the statutory deadline.

07

Valuation

PER
—
PBR
0.4×
ROE
-10.1%
EPS
-₩45,759
BPS
₩443,425
Dividend per share
₩6,000

Because the four most recent quarters total a KRW 733.2 billion attributable net loss, PER cannot be calculated on earnings, so a comparison built on book value and the pace of profit recovery is more factual. The price-to-book ratio sits well below 1x, meaning the share price is low relative to book net assets.

Attributable equity stood at KRW 7.06 trillion at year-end 2025, and how efficiently that book value converts into earnings is the central variable.

Over several years, the earnings base weakened from attributable net profit of KRW 802.7 billion in 2022 to a loss in 2025, while quarterly operating profit has moved back up in 2026.

Dividend yield moves with earnings and dividend capacity, so dividend capacity relative to earnings is the item to check in a loss phase. Among brokers, KB Securities said in a July 2026 report that it maintained a Buy rating and a target price of KRW 280,000.

The same report expected Q2 2026 operating profit to be in line with consensus on the bio recovery. Valuation interpretation depends on whether the operating profit recovery carries through to attributable net profit in the black.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Quarterly operating profit recovery

Operating profit bottomed at KRW 204.8 billion in Q4 2025 and then rose to KRW 238.1 billion in Q1 2026, KRW 257.6 billion in Q2 and KRW 309 billion in Q3. The operating margin recovery will be confirmed in the next annual report.

Overseas food expansion

Overseas food sales reached KRW 5.92 trillion in 2025, or 51.4% of food sales, which press reports described as the first time the share passed half. Q4 2025 overseas food sales of KRW 1.61 trillion were reported as a quarterly record.

Q3 2026 overseas food sales of KRW 1.51 trillion rose 3.7% year on year, led by global strategic products such as dumplings and packaged rice.

Specialty amino acids and methionine prices

Core materials operating profit in Q3 2026 was KRW 108.5 billion, up 36% year on year. Analysts said the sharp rise in methionine prices acted as a tailwind for the bio business.

09

Bear factors

Weak bio pricing

Bio segment operating profit fell to KRW 5.5 billion in Q1 2026, down 92.4% year on year. The company attributed the price pressure to low-cost bulk supply of feed-grade amino acids from China. The product line is highly exposed to industry conditions, so quarterly profit swings are large.

Pressure on food profitability

The company said foreign exchange valuation losses reduced net profit in Q3 2026. Higher freight and raw material costs have lifted expenses across food and materials. Prolonged weakness in domestic consumption is limiting profit recovery in the home market.

Accumulated losses and financial burden

The company swung to an attributable net loss of KRW 571.5 billion in 2025, and the four most recent quarters total a KRW 733.2 billion attributable net loss. The debt-to-equity ratio rose to 157.5% at year-end 2025 from 146.3% in 2024. Technical Solution still posted an operating loss of KRW 24.2 billion in Q3 2026.

10

Risk factors

FX and cost pressure

FX valuation losses have increased net profit volatility, while higher raw material and freight costs are weighing on food margins. These factors were cited together in reports on Q3 2026. As the overseas share grows, currency exposure grows with it.

Bio industry cycle

Feed-grade amino acids are sensitive to supply increases from China and to price swings. Q1 2026 bio operating profit falling to KRW 5.5 billion illustrates this. Whether a larger specialty mix narrows the swings is the point to watch.

Restructuring and leverage

Sale of the feed subsidiary, disposals of non-core assets and large investment in Technical Solution are proceeding at the same time. The debt-to-equity ratio was 157.5% at year-end 2025, with total liabilities of KRW 18.2 trillion. If restructuring is delayed, debt burden could slow the pace of profit recovery.

11

What to watch next

  1. Early February 2027 (estimated)

    Release of Q4 and full-year 2026 preliminary results. Whether the Q4 operating margin reached the company's 5% range and whether the bio price recovery showed up in Q4 profit are the key checks.

  2. End of March 2027

    Statutory deadline for the 2026 annual report. This is when full-year non-operating items and the discontinued-operations classification of the F&C division are confirmed in filed figures.

  3. Around May 2027

    Release of Q1 2027 results. Whether bio operating profit recovered from the KRW 5.5 billion level of Q1 2026 and whether attributable net profit stays in the black are the key checks.

  4. During 2027

    Start of operations at the new Hungary plant. Whether expanded European production supports overseas food profitability is the point to watch.

12

Overall view

CJ Cheiljedang had a difficult 2025, with operating profit of KRW 1.23 trillion and an attributable net loss of KRW 571.5 billion, but operating profit has risen for three consecutive quarters from Q1 to Q3 2026. The Q3 attributable profit of KRW 19.2 billion came after a Q2 loss.

Overseas food sales reached KRW 5.92 trillion in 2025, the first year the share passed half of food sales, and global strategic products such as dumplings and packaged rice led growth.

The bio business's quarterly profit swings sharply with prices, as the KRW 5.5 billion operating profit in Q1 2026 and the KRW 108.5 billion core materials profit in Q3 2026 show.

Strengths include the operating profit recovery, overseas food growth and the expansion of specialty amino acids, while weaknesses include bio pricing, FX and costs, and a four-quarter attributable net loss of KRW 733.2 billion. The 157.5% debt-to-equity ratio and execution risk in restructuring also warrant attention.

The next checkpoints are the Q4 and full-year 2026 results in early February 2027 and the filing of the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. kr.investing.com
  2. lkp.news
  3. press9.kr
  4. msg.ls-sec.co.kr
  5. betanews.net
  6. ket.kr
  7. ontojob.co.kr
  8. newsway.co.kr
  9. cjnews.cj.net
  10. news.nate.com
  11. biz.heraldcorp.com
  12. bloter.net
  13. foodnews.co.kr
  14. m.news.nate.com
  15. bloter.net
  16. insight.co.kr
  17. sisajournal-e.com
  18. cjnews.cj.net

Report written 2026-11-17 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis